SCHEMBL4927253

SCHEMBL4927253

NC(=O)c1ccc(O)c(NC(=O)Nc2cccc3cccc(N)c23)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA12 O43570 7/20 0.45
CA1 P00915 7/20 0.45
CA9 Q16790 7/20 0.45
CA2 P00918 6/20 0.45
H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 P62805 1/20 0.41
EP300 Q09472 1/20 0.41
PRMT1 Q99873 1/20 0.41
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 2/20 0.40
PARP1 P09874 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
LCK P06239 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC1 Q13547 2/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925227 0.85 RAB9A (0.50) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL4923902 0.81 RAB9A (0.51) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL4915647 0.80 LCK (0.50) CA12CA1CA9CA2H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16
SCHEMBL4915704 0.79 ROCK1 (0.44) KDM4ESMN1; SMN2POLBMEN1KMT2A
SCHEMBL4924988 0.76 CA12 (0.57) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL4920330 0.76 MDM4 (0.46) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL5919246 0.74 MAPT (0.62) KDM4ESMN1; SMN2POLBTRPV1MEN1
SCHEMBL4921362 0.73 MEN1 (0.58) CA12CA1CA9CA2POLB
SCHEMBL4915093 0.73 CA12 (0.48) CA12CA1CA9CA2KDM4E
SCHEMBL27701184 0.71 HDAC1 (0.42) CA12CA1CA9CA2H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
CN-101087601-A Compounds for inhibiting copper-containing amine oxidases and uses thereof GENMEDICA THERAPEUTICS SL (ES) 2007-12-12 CN disclosed
EP-1796681-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF Genmedica Therapeutics SL (ES) 2007-06-20 EP disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed
WO-2006013209-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF GENMEDICA THERAPEUTICS SL (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CA12 3438/4885CA1 2819/4885CA9 1988/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CA12 3541/4885CA1 3000/4885CA9 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.